Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors

European Respiratory Journal

Volumn 35, Issue 3, 2010, Pages 598-605

  Von Baum, H ^a   Welte, T ^b   Marre, R ^a   Suttorp, N ^c   Ewig, S ^d,e  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Thoraxzentrum Ruhrgebiet   (Germany)

^e Thoraxzentrum Ruhrgebiet   (Germany)

Author keywords

Community acquired pneumonia; Enterobacteriaceae; Pseudomonas aeruginosa

Indexed keywords

ADULT; ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DISEASE SEVERITY; ENTEROBACTERIACEAE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR;

ADULT; AGE FACTORS; AGED; COMMUNITY-ACQUIRED INFECTIONS; DATABASES, FACTUAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS;

EID: 77949690877     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00091809     Document Type: Article

References (31)

1. Ewig S. Community-acquired pneumonia: definition, epidemiology, and outcome. Semin Respir Infect 1999; 14: 94-102.
2. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162: 1849-1858.
3. Kang CI, Song JH, Oh WS, et al. Clinical outcomes and risk factors of community-acquired pneumonia caused by Gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2008; 27: 657-661.
4. Blanquer J, Blanquer R, Borras R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991; 46: 508-511.
5. Miyashita N, Shimizu H, Ouchi K, et al. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit 2008; 14: CR171-CR176.
6. Charles PG, Whitby M, Fuller AJ, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46: 1513-1521.
7. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-184.
8. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results froma large US database of culture-positive pneumonia. Chest 2005; 128: 3854-3862.
9. Guay DR. Guidelines for the management of adults with health care-associated pneumonia: implications for nursing facility residents. Consult Pharm 2006; 21: 719-725.
10. Micek ST, Kollef KE, Reichley RM, et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007; 51: 3568-3573.
11. Shorr AF, Zilberberg MD, Micek ST, et al. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008; 168: 2205-2210.
12. Shindo Y, Sato S, Maruyama E, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009; 135: 633-640.
13. Welte T, Suttorp N, Marre R. CAPNETZ - community-acquired pneumonia competence network. Infection 2004; 32: 234-238. (Pubitemid 39070604)
14. Mauch H, Lütticken R, Gatermann S, eds. MiQ 7. Infektionen der tiefen Atemwege. Teil I. Qualitätsstandards in der mikrobiologisch- infektiologischen Diagnostik. [Infection of the Deep Airways. Part I. Quality Standards in the Microbiological Diagnosis of Infectious Diseases.] Jena, Gustav-Fischer-Verlag, 1999.
15. Mauch H, Lütticken R, Gatermann S, eds. MiQ 8. Infektionen der tiefen Atemwege. Teil II. Qualitätsstandards in der mikrobiologisch- infektiologischen Diagnostik. [Infection of the Deep Airways. Part II. Quality Standards in the Microbiological Diagnosis of Infectious Diseases.] Jena, Gustav-Fischer-Verlag, 1999.
16. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307-316.
17. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016.
18. Lim I, Shaw DR, Stanley DP, et al. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust 1989; 151: 87-91.
19. Ewig S, Torres A. Severe community-acquired pneumonia. Clin Chest Med 1999; 20: 575-587.
20. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210-1216.
21. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165: 766-772.
22. Campbell SG, Marrie TJ, Anstey R, et al. Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department. Emerg Med 2003; 20: 521-523.
23. Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003; 123: 1142-1150.
24. Howard LS, Sillis M, Pasteur MC, et al. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect 2005; 50: 107-113.
25. Van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community-acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672-678.
26. Ortiz-Ruiz G, Vetter N, Isaacs R, et al. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53: Suppl. 2, ii59-ii66.
27. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405.
28. Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009; 48: 377-385.
29. Marrie TJ, Poulin-Costello M, Beecroft MD, et al. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99: 60-65.
30. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and reviewof the literature. Clin Infect Dis 2000; 31: 1349-1356.
31. Wendt C, Bock-Hensley O, von Baum H. Infection control in German nursing homes. Am J Infect Control 2006; 34: 426-429.